Profit growth of 369% is not the first! CXO industry revenue exposure in the first half of the year, these three CROs deserve attention.

Guide: Policy forces enterprise innovation, CXO industry fishing profits, the outbreak is "dangerous" is also "machine"! For a long time, policies such as collection and adjustment of the national health insurance catalogue have still forced pharmaceutical companies to innovate, and it is a basic requirement for enterprises to increase investment in research and development.
, the domestic innovation boom continues to ferment, enterprise research and development pipeline into the cash period at the same time, CXO enterprises will also usher in another wave of "word-of-mouth."
August 30, 260 pharmaceutical companies published their first-half annual reports, with cumulative growth rates of -2.3% and 2.1% respectively in the first half of the year.
, the innovation service industry chain due to the limited outbreak, and the increasing demand of the industry and other factors, the industry recovered the fastest.
10 key CXO companies in 2020H1 total revenue growth rate of 25.16%, the total home net profit growth rate of 89.52%, of which Q2 industry performance is significantly better than Q1, which may be Q2 overseas outbreak intensified, more overseas orders transferred to the domestic.
, CXO listed companies' gross margin of 2020H1 was basically stable compared with the previous financial data, but the net profit margin increased significantly.
partly due to the decline in the financial expense rate of some enterprises, the financial situation after financing is stable.
, on the other hand, the increase in corporate investment income affected the overall net profit margin of the sector.
Finally, with the domestic epidemic control is good, clinical business in June also recovered and showed positive growth, coupled with the increase of overseas outbreaks, the domestic CXO company technology progress is significant, the global competitive advantage is prominent, outsourcing market share is expected to continue to improve in a short period of time.
as the fastest recovery of domestic operations, Q2 single-quarter growth is strong, the industry's first.
first half of the year revenue of 7.231 billion yuan, net profit of 1.717 billion yuan, both data year-on-year or month-on-month growth is significant, especially in the first half of the net profit growth rate of 367 percent, second only to "quantum biology."
and in the U.S. district laboratory services and clinical trial services by the global new crown outbreak of a large negative impact, 2020Q2 single-quarter revenue still returned to nearly 30% growth, home net profit growth of 43%, can afford to be the industry leader.
sub-sectors, China's laboratory services, small molecule CDMO, U.S. laboratory services, clinical and other CRO services achieved revenue growth of 26.5%, 25.8%, 10.1% and 5.9% year-on-year, respectively.
china laboratory services and CDMO services Q2 fully resumed operations in the single quarter, is the main reason for Q2 and even the first half of the revenue growth.
same time, in the first half of 2020, while the performance of Drug Mingkang recovered, it also added about 600 customers and contributed revenue of 401 million yuan (up 26.7% YoY), the number of small molecule CDMO pipeline molecules It is also an increase of 269 (5 projects approved for listing and commercial production), after which the domestic clinical CRO and SMO business is expected to enter a gradual recovery phase, at least in the second half of the domestic business worry-free, and will take advantage of the outbreak to achieve sustained high growth throughout the year.
KangLongHuaChengKangLongHua adult report revealed that the realization of operating income of 2.19 billion yuan, up 34% YoY;
like Pharmaceutical Mingkang, as the second largest preclinical CRO company in China, the second quarter of the results growth is also better than expected, especially in the second quarter quarter quarter quarter-on-quarter performance improvement is very significant.
core business, the company's profit growth at the same time, the operating aspects are equally reluctant to lag behind, capacity expansion, scale expansion at the same time, actively seek external expansion space.
first half of this year, CMC business realized revenue of 510 million yuan, up 34.4% YoY, gross margin of 29%, clinical CRO business realized revenue of 240 million yuan, up 27.5% YoY, gross margin of 21.8%, laboratory business realized revenue of 1.43 billion yuan, up 35.3% YoY Gross margin was 41.3%, 463 pharmaceutical molecules or intermediates were completed, of which 35 were clinical phase III and 2 were commercialized, resulting in revenue of 506 million yuan, up 34.38% YoY, and 28 IND declarations were carried out for domestic customers during the period (20 simultaneous declarations of multiple countries).
's clinical business increased from 1,480 in 2019 to 2,404, and the total number of employees increased by 19% from the end of 2019, maintaining a relatively fast growth rate.
Overall, the current overseas epidemic is becoming increasingly severe, further prompting overseas pharmaceutical companies to seek china's CXO enterprise cooperation, pharmaceutical research and development and production outsourcing penetration rate further improved, industrial transfer further accelerated, the company's revenue mainly from overseas, the beneficiary industry transfer trend, coupled with the company's business development accelerated, performance achieved high-speed growth.
Medici Q2 single-quarter recovery of high growth, service capacity continued to improve, as a small volume but better than the focus of the pre-clinical CRO standard, the listing of the company is conducive to further rapid expansion, preclinical integrated service capabilities are expected to continue to improve, under the CRO track dividend into a rapid expansion of the scale of the growth stage.
2020H1 revenue, home-to-home net profit and home-to-home net profit increased by 31.3%, 73.2% and 75.6% year-on-year, respectively, of which 2020Q1 achieved rapid recovery due to the slowing of income growth due to the impact of the outbreak and delayed resumption of work.
's growth is mainly due to the continued improvement of corporate service capabilities.
this is reflected in the continued growth of its market orders, customer structure and business structure continued optimization.
In the first six months of 2020, Medici added more than 100 new customers, with a new signing value of 530 million yuan, up 106.41 percent year-on-year, and 19 new drugs and generics projects involved in research and development have been approved for clinical trials by NMPA.
As Medici puts it, as its core competitiveness, Medici's audience is the early stage of research and development of "domestic small and medium-sized pharmaceutical companies and emerging biopharmaceutical technology companies with relatively weak research and development of new drugs", compared with large multinational CRO and local leading companies.
"one-stop service", with cost-effective, convenient communication and other advantages.
and with the advent of the era of national innovation, as the vast majority of pharmaceutical manufacturers, small and medium-sized enterprises innovation needs will even be far greater than large enterprises, the prospects are huge.
On the other hand, although Medici and in recent years have fully demonstrated its strong growth momentum, but compared with the peer-leading enterprises still have a gap is still not small, to achieve the ambition of the heart, there is still a long way to go.
Summary 2020 is an unfortunate year for the people of the whole country or most enterprises, but biased is such an era is the "heroes of chaos" generation out of the era, CXO industry by "epidemic" opportunity, just completed another internal sublimation.
Domestic aspects, "generic drugs-based" to "innovation-oriented" industry upgrading is an inevitable trend, as long as CDE approved new drugs are still increasing, the golden age of innovative drugs continues, the CXO market is expected to continue to show high-speed growth;
(in the case of CDMO, where big European pharmaceutical companies used to favour CDMO companies in Europe, europe is now affected by the outbreak and will nurture CDMO suppliers in China from the point of view of stabilizing supply chain systems).
Industry supply side, industry demand side, local enterprise capacity expansion three synergies, no doubt the first half of the outbreak is not only a test of CXO, but also a great opportunity given by God, the can go to heaven and earth, can not be doomed to the flag, seize the opportunity seems very important! Recommended reading: 1. Huahai Pharmaceuticals first half net profit growth of 72.77 percent, cost control advantages, can we start sailing again? 2. The stock price soared 8 times, the profit increased 115.51 percent, but behind the crisis 3.3 years to triple, according to this list to buy pharmaceutical stocks, wages doubled is not a thing! 4.48 new shares raised more than $11 billion! Under the outbreak, U.S. stocks biopharmaceutical IPO again boom.